AstraZeneca wins US approval of first rare thyroid cancer drug
This article was originally published in Scrip
Executive Summary
AstraZeneca won US approval 6 April of its multitargeted kinase inhibitor vandetanib as a treatment for symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease – the first treatment ever approved by the US FDA for that rare form of cancer.